Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
OCULAR THERAPEUTIX, INC director and officer Pravin Dugel reported bona fide gifts of Common Stock. On June 16, 2026, he reported two gift transactions totaling 100,184 shares, including 50,092 shares transferred to his spouse for no consideration.
After these transactions, Dugel reports 2,547,078 shares held directly, 694,811 shares held indirectly through the Pravin Dugel 2024 Irrevocable Trust, and 50,092 shares held indirectly by his spouse.
Ocular Therapeutix director Charles M. Warden received new equity awards as part of board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, boosting his direct holdings to 100,464 shares.
He was also granted options for 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest in full on the first anniversary of the grant date, or earlier immediately before the next annual stockholder meeting, as long as he remains on the board.
Ocular Therapeutix director Adrienne L. Graves received new equity awards as part of her board compensation. She was granted 14,000 restricted stock units, each representing one share of common stock, increasing her direct common stock holdings to 64,000 shares after the award.
She was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest 100% on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving on the board.
Ocular Therapeutix Chief Financial Officer Jason Shand Robins received new equity awards as part of his compensation. He was granted 15,441 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 68,097 shares after the award. He was also granted an option to buy 14,024 shares of common stock at an exercise price of $8.74 per share, expiring in 2036. The RSUs vest over three years in three equal annual installments, and the stock option vests monthly over four years, both contingent on his continued service with the company.
Hong Seung Suh reported acquisition or exercise transactions in this Form 4 filing.
Ocular Therapeutix director Seung Suh Hong received new equity awards as part of board compensation. He was granted 14,000 restricted stock units, each representing one future share of common stock, and 44,000 stock options to buy common shares at $8.74 per share.
The awards vest in full on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, as long as he continues serving on the board. After the grant, he directly holds 60,933 common shares and 44,000 options.
Ocular Therapeutix director Richard L. Lindstrom, MD received new equity awards as board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, and 44,000 stock options with an exercise price of $8.74 per share expiring on June 9, 2036.
Both the RSUs and options vest 100% on the first anniversary of the grant date or, if earlier, immediately before the next annual meeting of stockholders, provided he continues to serve on the board. Following the RSU grant, he directly owns 260,933 common shares.
Ocular Therapeutix director Merilee Raines received new equity awards. On June 10, 2026, she was granted 14,000 restricted stock units, each representing one share of common stock, under the company’s 2021 Stock Incentive Plan.
Subject to her continued board service, these RSUs vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, whichever comes first. She also received stock options for 44,000 shares at an exercise price of $8.74 per share, expiring on June 9, 2036, with similar vesting conditions. Following the grant, she directly holds 60,933 shares of common stock, in addition to the new option award.
Ocular Therapeutix director Leslie J. Williams received new equity awards. On June 10, 2026, Williams was granted 14,000 shares of common stock as restricted stock units under the company’s 2021 Stock Incentive Plan. These RSUs vest in full after one year of continued board service or just before the next annual stockholder meeting.
Williams was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036, with the same one-year vesting schedule tied to continued board service. After these grants, Williams directly holds 65,433 shares of common stock and 44,000 stock options.
Ocular Therapeutix reported that stockholders approved Amendment No. 5 to its 2021 Stock Incentive Plan, increasing the number of shares issuable under the plan by 10,000,000 shares. This expands the equity pool available for employee, director, and officer compensation.
The Board also appointed Jason Robins, previously interim Chief Financial Officer, as Chief Financial Officer. His annual base salary will be $535,100 from July 1, 2026, with a target cash bonus of 45% of salary. He received an option for 14,024 shares and a restricted stock unit award for 15,441 shares, subject to multi‑year vesting. Stockholders supported holding future advisory votes on executive compensation every year.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share. The sale was made under a pre-established durable automatic sale instruction to cover tax withholding tied to restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following this transaction, she directly holds 300,079 shares of common stock.